Send to

Choose Destination
ACG Case Rep J. 2018 Feb 28;5:e17. doi: 10.14309/crj.2018.17. eCollection 2018.

Emerging Role of Vedolizumab in Managing Refractory Immune Checkpoint Inhibitor-Induced Enteritis.

Author information

Vita-Salute San Raffaele University, Milan, Italy.
Sanford School of Medicine, University of South Dakota, Sioux Falls, SD.
Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC.
Department of Pathology, Medstar Georgetown University Hospital, Washington, DC.
Division of Gastroenterology, Medstar Georgetown University Hospital, Washington, DC.


We report a 62-year-old white woman with metastatic choroidal melanoma who developed immune checkpoint inhibitor (ICI)-induced enteritis and grade 3 diarrhea refractory to steroids and infliximab. Her diarrhea quickly resolved after infusion of vedolizumab, and the patient was able to taper down steroids. Vedolizumab's mechanism of action and its gut specificity have the potential to reverse immune-induced enterocolitis without neutralizing or reversing the therapeutic benefit of ICI on the malignancy.

Supplemental Content

Full text links

Icon for Wolters Kluwer Icon for PubMed Central
Loading ...
Support Center